



OPEN ACCESS

EDITED BY

Gaetano Isola,
University of Catania, Italy

REVIEWED BY

Victor Martinez-Aguilar,
Universidad Autonoma de Yucatan, Mexico
Florence Carrouel,
Université Claude Bernard Lyon 1, France

*CORRESPONDENCE

Bruno Bueno-Silva
✉ brunobue@gmail.com

RECEIVED 26 April 2023

ACCEPTED 13 July 2023

PUBLISHED 31 July 2023

CITATION

Bueno MR, Dudu-Silva G, Macedo TT,
Gomes APdAP, Rodrigues Oliveira Braga A,
Aguilar Silva LD and Bueno-Silva B (2023)
Lactobacillus acidophilus impairs the
establishment of pathogens in a subgingival
multispecies biofilm.
Front. Dent. Med. 4:1212773.
doi: 10.3389/fdmed.2023.1212773

COPYRIGHT

© 2023 Bueno, Dudu-Silva, Macedo, Gomes,
Rodrigues Oliveira Braga, Aguiar Silva and
Bueno-Silva. This is an open-access article
distributed under the terms of the [Creative
Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use,
distribution or reproduction in other forums is
permitted, provided the original author(s) and
the copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic practice.
No use, distribution or reproduction is
permitted which does not comply with these
terms.

Lactobacillus acidophilus impairs the establishment of pathogens in a subgingival multispecies biofilm

Manuela Rocha Bueno¹, Gustavo Dudu-Silva²,
Tatiane Tiemi Macedo², Aline Paim de Abreu Paulo Gomes²,
Arthur Rodrigues Oliveira Braga², Lucas Daylor Aguiar Silva²
and Bruno Bueno-Silva^{2,3}

¹Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil, ²Dental Research Division, Guarulhos University, Guarulhos, Brazil, ³Department of Bioscience, Piracicaba Dental School, University of Campinas (UNICAMP), Piracicaba, Brazil

The present study evaluated the antibiofilm effects of *Lactobacillus acidophilus* within a subgingival multispecies biofilm. *Lactobacillus acidophilus* (La5) at 1×10^2 , 1×10^4 , and 1×10^6 were included at the beginning of biofilm formation, which lasted 7 days. The biofilms comprised 33 periodontitis-related bacterial species and the Calgary Biofilm device was used. At the end, DNA–DNA hybridization (checkerboard) was performed. A Kruskal–Wallis test followed by a Dunn *post hoc* test were performed ($p \leq 0.05$). La5 at 1×10^4 and 1×10^6 reduced the total counts of biofilm and the proportions of red and green complexes when compared to the control biofilm without La5 ($p \leq 0.05$). La5 at 1×10^4 increased the proportions of *Actinomyces* complex compared to the controls ($p \leq 0.05$). Both La5 at 1×10^4 and 1×10^6 decreased levels of 20 and 14 distinct species, respectively, including *Porphyromonas gingivalis*, *Prevotella intermedia*, *Fusobacterium nucleatum polymorphum*, and *Parvimonas micra* compared to the control ($p \leq 0.05$). Only La5 at 1×10^4 reduced the levels of *Tannerella forsythia*, *Fusobacterium periodonticum*, and *Aggregatibacter actinomycetencomytans* compared to the control ($p \leq 0.05$). *L. acidophilus* inhibited establishing periodontic pathogens from red complex such as *P. gingivalis* and *T. forsythia* in a subgingival multispecies biofilm.

KEYWORDS

subgingival biofilm, periodontitis, *Lactobacillus acidophilus*, bacteria, probiotics

1. Introduction

Periodontitis is clinically characterized by the loss of protective and supporting tissues of the teeth. Such destruction involving loss of periodontal ligament, cement, and alveolar bone results in a proper niche to a dysbiotic microbiome, which results in an intense immune-inflammatory response (1). The dysbiosis starts without clinical signs (2) and this bacteria-inflammation binomial remains in a positive feedback loop if the patient is not properly treated. New findings regarding periodontal disease have changed the perspective regarding its etiology and the role of those considered “periodontal pathogens,” showing a more diverse and complex periodontitis-associated microbiota, related to dysbiosis, i.e., a shift in the proportion of beneficial and pathogenic microorganisms that disrupts the homeostasis seen in health (3).

Traditionally, periodontal treatment requires control of risk factors (such as diabetes, smoking, insufficient biofilm control), mechanical debridement of affected surfaces, and

administration of systemic antibiotics in severe cases (4); however, studies show that due to a biofilm characteristic called resilience, after 1 year of treatment, pathogenic bacteria tend to increase in proportion, and this may lead to disease recurrence (5). In this regard, several adjunctive therapies have been studied, such as antimicrobial photodynamic therapy (6), combinations of antibiotics (6), statins (7), and probiotics (8), in order to prevent recolonization and propagation of bacterial pathogens and/or modulate the immune response, regaining the microbiome ecological balance (9).

Probiotics are living microorganisms that may promote benefits in health (10) and they have been studied as adjunctive therapy in periodontal treatment due to their ability to decrease the colonization of pathogens and to modulate host immune response. *In vitro* studies (11, 12) have shown that gingival epithelial cells (GECs) infected either with *Aggregatibacter actinomycetemcomitans* or *Porphyromonas gingivalis* and treated with different strains of probiotics could reduce the adhesion of pathogens to GECs as well as attenuating the release of important inflammatory cytokines, such as IL-1 β , CXCL-8, and GM-CSF. In addition, the postbiotics derived from lactobacilli have been shown to reduce *A. actinomycetemcomitans* biofilm formation and to decrease the expression of virulence factors, such as cytolethal distending toxin and leukotoxin (13). Moreover, an *in vivo* study using a microbial consortium to induce experimental periodontitis containing *P. gingivalis*, *Fusobacterium nucleatum*, *Prevotella intermedia*, and *Streptococcus gordonii* was successfully treated when the animals were inoculated with probiotics, by reducing alveolar bone loss (14). However, all the aforementioned studies showed that the effectiveness of treatment with probiotics depends on the strain used, since some strains have an inflammatory potential.

To add to the knowledge of the use of probiotics in the control of dysbiosis seen in periodontal disease, we evaluated whether *L. acidophilus* La5 was able to interfere in a subgingival biofilm composition through an *in vitro* model.

2. Materials and methods

2.1. Formation of multispecies subgingival biofilm

An *in vitro* multispecies biofilm was developed, as explained by Miranda et al. (15) and Pinguero et al. (16), with inoculum alterations. The bacterial species used in the multispecies biofilm model are listed in Table 1. All bacterial species were procured from the ATCC company.

Tryptone soy agar plus 5% sheep blood (Probac, São Paulo, Brazil) was the medium to grow the majority of the species under anaerobic conditions (85% nitrogen, 10% carbon dioxide, and 5% hydrogen), while *Eubacterium nodatum* was cultivated on fastidious anaerobic agar plus 5% sheep blood. *Porphyromonas gingivalis* was grown on tryptone soy agar plus

TABLE 1 Species cultivated in multispecies biofilms grouped into the bacterial complexes (17).

Multispecies biofilm strains
Actinomyces complex
<i>Actinomyces naeslundii</i> ATCC 12104
<i>Actinomyces oris</i> ATCC 43146
<i>Actinomyces gerencseriae</i> ATCC 23840
<i>Actinomyces israelii</i> ATCC 12102
Purple complex
<i>Veillonella parvula</i> ATCC 10790
<i>Actinomyces odontolyticus</i> ATCC 17929
Yellow complex
<i>Streptococcus sanguinis</i> ATCC 10556
<i>Streptococcus oralis</i> ATCC 35037
<i>Streptococcus intermedius</i> ATCC 27335
<i>Streptococcus gordonii</i> ATCC 10558
<i>Streptococcus mitis</i> ATCC 49456
Green complex
<i>Aggregatibacter actinomycetemcomitans</i> ATCC 29523
<i>Capnocytophaga ochracea</i> ATCC 33596
<i>Capnocytophaga gingivalis</i> ATCC 33624
<i>Eikenella corrodens</i> ATCC 23834
<i>Capnocytophaga sputigena</i> ATCC 33612
Orange complex
<i>Campylobacter showae</i> ATCC 51146
<i>Eubacterium nodatum</i> ATCC 33099
<i>Fusobacterium nucleatum vincentii</i> ATCC 49256
<i>Parvimonas micra</i> ATCC 33270
<i>Fusobacterium nucleatum polymorphum</i> ATCC 10953
<i>Fusobacterium periodonticum</i> ATCC 33693
<i>Prevotella intermedia</i> ATCC 25611
<i>Streptococcus constellatus</i> ATCC 27823
Red complex
<i>Porphyromonas gingivalis</i> ATCC 33277
<i>Tannerella forsythia</i> ATCC 43037
Other
<i>Streptococcus anginosus</i> ATCC 33397
<i>Streptococcus mutans</i> ATCC 25175
<i>Selenomonas noxia</i> ATCC 43541
<i>Propionibacterium acnes</i> ATCC 11827
<i>Gemella morbillorum</i> ATCC 27824

yeast extract and supplemented with 1% hemin, 5% menadione, and 5% sheep blood. *Tannerella forsythia* was cultivated on tryptone soy agar plus yeast extract, supplemented with 1% hemin, 5% menadione, 5% sheep blood, and 1% *N*-acetylmuramic acid. All species were grown on agar plates for 24 h and were then moved to glass tubes with BHI culture medium (Becton Dickinson, Sparks, MD, USA) enriched with 1% hemin. After 24 h of growth on conical tubes, the optical density (OD) was adjusted for the inoculum to have about 10⁸ cells/mL of each bacterial species. A dilution of individual bacterial cell suspensions was performed, and 100- μ L aliquots containing 10⁶ cells from each species were mixed with 11,700 μ L of BHI broth supplemented with 1% hemin and 5% sheep blood to acquire a 15-mL inoculum.

The multispecies biofilm model was established using a Calgary biofilm device in a 96-well plate (Nunc; Thermo Scientific, Roskilde, Denmark). A 150- μ L aliquot of the inoculum was placed into each well, corresponding to $\sim 1 \times 10^4$ cells of each bacterial species, except for *P. gingivalis* and *Prevotella intermedia*, whose inocula were modified to 2×10^4 cells. A lid comprising polystyrene pins was utilized to cover the 96-well plate (Nunc TSP System; Thermo Scientific, Roskilde, Denmark). Coated plates were incubated at 37°C under anaerobic conditions. On day 3, the medium was replaced with fresh BHI broth supplemented with 1% hemin and 5% sheep blood, and the biofilm was maintained at 37°C under anaerobic conditions for another 4 days to achieve 7-day-old biofilms (15, 16). Three distinct experiments were performed in triplicate.

2.2. Preparation of *Lactobacillus acidophilus* (La5)

L. acidophilus La5TM (CHR Hansen Holding A/S, Hørsholm, Denmark) was used. Before the experiments, the strain was stored in 20% glycerol at -80°C . *L. acidophilus* La5 was cultivated under microaerophilic conditions in Lactobacilli MRS broth and agar (Lactobacilli MRS, Difco). Then, bacteria were grown in liquid media until the midlog phase. After that, the suspension was adjusted to an OD 590 nm ~ 0.9 , corresponding to 2×10^8 CFU/mL. Then, the inoculum values of La5 were adjusted to final values of 1×10^2 , 1×10^4 , and 1×10^6 CFU/mL for each group of analysis.

2.3. DNA–DNA hybridization (checkerboard)

Three 7-day biofilm coated pins from each group and from each experiment were washed in phosphate-buffered solution and transferred to microcentrifuge tubes containing 150 μ L of TE buffer (10 mM Tris-HCl, 1 mM EDTA (pH 7.6)), followed by the addition of 100 μ L of 0.5M NaOH. The tubes containing the pins and the final solution were boiled for 10 min, and the solution was neutralized with 0.8 mL of 5M ammonium acetate. The samples were analyzed individually for the presence and quantity of 33 bacterial species using the DNA–DNA hybridization technique. Briefly, biofilm samples were lysed by boiling them and by the ammonium acetate as described above. The corresponding DNA was plated onto a nylon membrane using a Minislot device (Immunetics, Cambridge, MA, USA). After attachment to the membrane, the DNA samples were placed in a Miniblotter 45 (Immunetics). Digoxigenin labeled with DNA probes of the entire genome of the subgingival species was hybridized to the individual lanes of the Miniblotter 45. The membranes were washed, and DNA probes were detected using a specific antibody against digoxigenin conjugated to phosphatase alkaline. The signals were detected using AttoPhos substrate (Amersham Life Sciences, Arlington Heights, IL, USA), and the results were obtained using Typhoon Trio Plus (Molecular

Dynamics, Sunnyvale, CA, USA). Two lanes in each run contained standards with 10^5 and 10^6 cells of each strain. Signals obtained with the Typhoon Trio were converted into absolute counts by comparison with the standards on the same membrane. Failure to detect a signal was recorded as zero. The values obtained upon treatment with La5 were compared to those of the negative and positive controls (15, 18). The data were analyzed using a Kruskal–Wallis test followed by a Dunn *post hoc* test ($p \leq 0.05$).

3. Results

Figure 1 shows the counts of *L. acidophilus* (La5) within the subgingival multispecies biofilm. $La5 \times 10^6$ presents three times more counts than $La5 \times 10^2$ ($p \leq 0.05$). $La5 \times 10^4$ counts did not differ from any other group ($p \geq 0.05$).

Figure 2 shows the total counts of all microorganisms included within the biofilm model. $La5 \times 10^4$ and $La5 \times 10^6$ significantly reduced the biofilm amount when compared to biofilm without any treatment ($p \leq 0.05$). Data from the $La5 \times 10^2$ were not significant ($p \geq 0.05$) to any of the other groups; therefore, this group was excluded from the next analysis.

Figure 3 shows the La5 effects on bacterial complexes, as determined by Socransky et al. (19). Both $La5 \times 10^4$ and $La5 \times 10^6$ significantly decreased proportions of pathogens in the red complex and those of the beneficial green complex to a very similar number when compared to control ($p \leq 0.05$). On the other hand, both $La5 \times 10^4$ and $La5 \times 10^6$ significantly increased the proportions of other complexes ($p \leq 0.05$). Finally, only $La5 \times 10^4$ increased proportions of bacteria in the health-associated actinos complex when compared to the control group ($p \leq 0.05$).

Figure 4 demonstrates the results of the counts of each bacterial species within multispecies biofilm. $La5 \times 10^4$ significantly diminished the counts of 20 species while $La5 \times 10^6$ decreased the counts of 14 species ($p \leq 0.05$) when compared to counts of bacterial species within biofilm without any treatment. Both treatment groups share inhibitory effects on 12 species, highlighting the effects on *P. gingivalis* (red complex), *Campylobacter showae*, *Campylobacter gracilis*, *Parvimonas micra*, *Fusobacterium nucleatum polymorphum*, and *Prevotella intermedia* (members of the orange complex). Of even greater impact, only $La5 \times 10^4$ significantly reduced the counts of *T. forsythia*, another member of the red complex, and *Fusobacterium periodonticum*, a member of the orange complex. In contrast, $La5 \times 10^6$ increased the counts of *Eubacterium nodatum*, a member of the orange complex. When comparing both La5 treatments, $La5 \times 10^4$ significantly reduced the counts of *Streptococcus oralis*, *Aggregatibacter actinomycetencomytans*, *Eikenella corrodens*, *Fusobacterium nucleatum vicentii*, and *Streptococcus constellatus* ($p \leq 0.05$). Therefore, the subgingival multispecies biofilm formed in the presence of $La5 \times 10^4$ presented lower counts of three major periodontic pathogens such as *P. gingivalis*, *T. forsythia*, and *A. actinomycetencomytans*.




FIGURE 1
 Mean counts of La5 after 7 days of biofilm formation within a multispecies biofilm. Different letters indicate statistical significance between groups by Kruskal–Wallis followed by Dunn’s *post hoc* test ($p \leq 0.05$). $La5 \times 10^2$ means initial inoculum with $La5 \times 10^2$ CFU/mL; $La5 \times 10^4$ means initial inoculum with $La5 \times 10^4$ CFU/mL; and $La5 \times 10^6$ means initial inoculum with $La5 \times 10^6$ CFU/mL.





FIGURE 2
 Mean total counts of multispecies biofilm without any treatment (control) and treated with $La5 \times 10^2$, $La5 \times 10^4$, and $La5 \times 10^6$. Different letters indicate statistical significance between groups by Kruskal–Wallis followed by Dunn’s *post hoc* test ($p \leq 0.05$). $La5 \times 10^2$ means initial inoculum with $La5 \times 10^2$ CFU/mL; $La5 \times 10^4$ means initial inoculum with $La5 \times 10^4$ CFU/mL; and $La5 \times 10^6$ means initial inoculum with $La5 \times 10^6$ CFU/mL.

4. Discussion

Periodontitis is a chronic multifactorial inflammatory disease associated with a mainly structured biofilm, composed of specific microorganisms and their products, that may guide to tissue damage (20). Herein, *L. acidophilus* reduced biofilm total counts, the red complex proportion, and the amount of the mainly periodontopathogens, such as *P. gingivalis*, *T. forsythia*,

P. micra, *F. nucleatum polymorphum*, *P. intermedia*, and *A. actinomycetencomytans*, within a subgingival multispecies biofilm model.

The subgingival biofilm is considered the main etiological factor of periodontal disease. The classical work by Socransky et al. (17) grouped bacterial species in the subgingival biofilm into microbial complexes. The yellow (*Streptococcus* spp.), green (*Campylobacter* spp.), purple (*V. parvula* and *A. odontolyticus*),



and actinos (*Actinomyces* spp.) complexes were associated with periodontal healthy conditions, while the orange complex (*P. micra*, *Fusobacterium* spp., and *P. intermedia*) was associated to transition from health to disease. Finally, the red complex (*P. gingivalis*, *T. forsythia*, and *Treponema denticola*) was associated with diseased conditions of the periodontum. Although nowadays it is known that the presence of bacterial species in periodontal-diseased sites is much more diverse than the 40 species included in the Socransky complexes (21), this analysis is still an excellent parameter to evaluate antimicrobial effects until new knowledge establish novel periodontal pathogens.

Currently, an agent acting only on the pathogens and their virulence factors is preferable to a broad-spectrum antimicrobial agent since some bacterial species are associated with healthy conditions (22). In this way, both La5 × 10⁴ and La5 × 10⁶ reduced the red complex from 27% to 2% and 1%, respectively. This is a considerable reduction in the same levels observed with the aid of well-known antimicrobials, such as chlorhexidine and cetylpyridinium chloride (23). In line with the current concept, La5 × 10⁴ increased proportions of actinomyces complex associated with healthy conditions.

The present data corroborate the literature that shows that *L. acidophilus* diminishes the *P. gingivalis* abundance within mono and three-species biofilm (24). In addition, the quantities of an *A. actinomycetencomytans* monospecies biofilm were reduced by *L. acidophilus* La5 (13). Thus, *L. acidophilus* La5 has a potential effect as an antibiofilm agent, increasing the scientific basis for future clinical studies for the treatment of periodontitis.


P. gingivalis, *T. forsythia*, and possibly other oral bacteria species have been recently indicated as strategic actors in the dysbiosis of the subgingival biofilm, leading to periodontal disease. The presence of these microorganisms can stimulate the transition from a health-associated biofilm to a pathogenic one and start the destruction of tissue due to an increased immunoinflammatory reaction (25). In these circumstances, the reduction of both bacteria by La5 × 10⁴ is an outstanding result,

explained by the physical proximity of microorganisms within the biofilm that increases the probability of synergistic or antagonistic interactions.

Lactobacillus spp. produces several antimicrobial compounds, such as hydrogen peroxide, lactate, teichoic acid, and bacteriocins (26, 27), that can inhibit a range of microorganisms, such as *P. gingivalis* and *A. actinomycetencomitans*. Moreover, studies show that lactobacilli can alter the transcription profile of *P. gingivalis* and *A. actinomycetencomitans*, thus interfering in their ability to colonize the host tissues and subvert the immune response; for example, by downregulating the expression of *fimA*, an important virulence factor-related fimbriae formation of *P. gingivalis*, and reduction of leukotoxin (*ltxA*) produced by *A. actinomycetencomitans*.

Another important finding is the reduction of all species of *Fusobacterium* genera present in the model (*F. nucleatum vincentii*, *F. nucleatum polymorphum*, and *F. periodonticum*) by La5 × 10⁴. The genera *Fusobacterium* plays a relevant role in the transition from periodontal health to disease (28). *Fusobacterium nucleatum* is indicated as the most prevalent anaerobic, Gram-negative species in the late periods of the disease and has been considered a possible periodontal pathogen (29). Some authors (29, 30) have reported that the presence of *F. nucleatum* is mainly associated with individuals with periodontitis and periodontal abscesses, and its levels are reduced after effective periodontal therapy. As an intermediate colonizer of dental biofilm and one of the first Gram-negative species to be stable in the subgingival biofilm, *Fusobacterium* species play an important role in the interactions between Gram-positive and Gram-negative species, contributing to the colonization of other anaerobic species, including the pathogens of the red complex (28).

The limitations of this study include the absence of *Treponema denticola* in the model. Although relevant to the development of periodontitis, previous articles using the same model did not include it due to the difficulty of growing this bacterium *in vitro*. Another limitation is the time of contact of LA5 with the biofilm. How to administer the lactobacilli *in vivo* to keep it



stuck to the biofilm from the beginning of periodontal multispecies biofilm development? These are challenges to be overcome in future studies.

The inflammatory response plays a crucial role in the tissue destruction occurring during periodontal disease and probiotics, in addition to exerting action in the colonization of pathogens, can modulate the exacerbated immune host response (31). *In vitro* studies using GECs (11, 12) and human macrophages

(32) showed the downregulation of inflammatory cytokines when cells were challenged either with *P. gingivalis* or *A. actinomycetecomytans* and treated with lactobacilli, such as interleukin-1β, a cytokine involved in bone resorption under pathological conditions. Other cytokines/chemokines also presented reduced levels by La5 such as CXCL-8, GM-CSF, and TNF-α. This immunomodulatory response accompanied by the antibiofilm effect indicate that this probiotic strain is a potential candidate for adjunctive therapy in periodontal treatment.

Furthermore, a recent meta-analysis showed that using probiotics as an adjunctive therapy promoted a clinical attachment level gain and reduction of probing pocket depth at 3 and 12 months, which are the main clinical goals in periodontal treatment (33). In addition, a systematic review concluded that administering probiotics as an adjuvant treatment improved the clinical parameters and decreased the concentration of the main periodontal pathogens without causing any side effects (33).

To limit the use of antibiotics and the risk of bacterial resistance, as well as to avoid undesirable effects by repeated therapy, efforts to optimize therapeutic procedures addressing the microbial colonization and recolonization of the periodontal pocket are crucial. Probiotics seem to be a reasonable alternative and our study elucidates that the co-culture of *L. acidophilus* La5 in a multispecies biofilm is capable of reducing the red complex and increasing the *Actinomyces* complex, providing an exciting strategy for the control of dysbiosis. However, more studies elucidating their mechanism of action and the correct timing, quantity, and which strain to be used are still necessary.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

Ethical review and approval was not required for this study in accordance with the national legislation and the institutional requirements.

Author contributions

BB-S drew the project, planned the assays, and wrote the manuscript. MB planned and ran the assays and helped write the manuscript. GD-S, TM, AG, AR, and LA helped run the assays. All authors contributed to the article and approved the submitted version.

Funding

MB was supported by scholarships from the Sao Paulo Research Foundation (FAPESP; no. 2017/16377-7). GS and TM received a

scholarship from the Coordination of Superior Level Staff Improvement (CAPES). AG and AR received an undergraduate scholarship from the National Council for Scientific and Technological Development (CNPq). LA pursued a scholarship from the Latin American Oral Health Association (LAOHA).

Conflict of interest

The author BB-S declared that they were an editorial board member of *Frontiers*, at the time of submission. This had no impact on the peer review process and the final decision.

References

- Armitage GC. Periodontal diagnoses and classification of periodontal diseases. *Periodontol* 2000. (2004) 34:9–21. doi: 10.1046/j.0906-6713.2002.003421.x
- Carrouel F, Viennot S, Santamaria J, Veber P, Bourgeois D. Quantitative molecular detection of 19 major pathogens in the interdental biofilm of periodontally healthy young adults. *Front Microbiol*. (2016) 7:840. doi: 10.3389/fmicb.2016.00840
- Hajishengallis G, Chavakis T, Lambris JD. Current understanding of periodontal disease pathogenesis and targets for host-modulation therapy. *Periodontol* 2000. (2020) 84(1):14–34. doi: 10.1111/prd.12331
- Sanz M, Herrera D, Kerschull M, Chapple I, Jepsen S, Beglundh T, et al. Treatment of stage I–III periodontitis—the EFP S3 level clinical practice guideline. *J Clin Periodontol*. (2020) 47(Suppl 22):4–60. doi: 10.1111/jcpe.13290
- Rosier BT, Marsh PD, Mira A. Resilience of the oral microbiota in health: mechanisms that prevent dysbiosis. *J Dent Res*. (2018) 97(4):371–80. doi: 10.1177/0022034517742139
- Ren C, McGrath C, Jin L, Zhang C, Yang Y. The effectiveness of low-level laser therapy as an adjunct to non-surgical periodontal treatment: a meta-analysis. *J Periodontol Res*. (2017) 52(1):8–20. doi: 10.1111/jre.12361
- Petit C, Batool F, Bugueno IM, Schwinte P, Benkirane-Jessel N, Huck O. Contribution of statins towards periodontal treatment: a review. *Mediators Inflamm*. (2019) 2019:6367402. doi: 10.1155/2019/6367402
- Canut-Delgado N, Giovannoni ML, Chimenos-Kustner E. Are probiotics a possible treatment of periodontitis? Probiotics against periodontal disease: a systematic review. *Br Dent J*. (2021). doi: 10.1038/s41415-021-3624-5. [Epub ahead of print]
- Balta MG, Papathanasiou E, Blix IJ, Van Dyke TE. Host modulation and treatment of periodontal disease. *J Dent Res*. (2021) 100(8):798–809. doi: 10.1177/0022034521995157
- FAO/WHO. *Working group report on drafting guidelines for the evaluation of probiotics in food London*. London: Ontario, ON (2022).
- Albuquerque-Souza E, Balzarini D, Ando-Sugimoto ES, Ishikawa KH, Simionato MRL, Holzhausen M, et al. Probiotics alter the immune response of gingival epithelial cells challenged by *Porphyromonas gingivalis*. *J Periodontol Res*. (2019) 54(2):115–27. doi: 10.1111/jre.12608
- Bueno MR, Ishikawa KH, Almeida-Santos G, Ando-Sugimoto ES, Shimabukuro N, Kawamoto D, et al. Lactobacilli attenuate the effect of *Aggregatibacter actinomycetemcomitans* infection in gingival epithelial cells. *Front Microbiol*. (2022) 13:846192. doi: 10.3389/fmicb.2022.846192
- Ishikawa KH, Bueno MR, Kawamoto D, Simionato MRL, Mayer MPA. Lactobacilli postbiotics reduce biofilm formation and alter transcription of virulence genes of *Aggregatibacter actinomycetemcomitans*. *Mol Oral Microbiol*. (2021) 36(1):92–102. doi: 10.1111/omi.12330
- Shimabukuro N, Cataruci ACS, Ishikawa KH, de Oliveira BE, Kawamoto D, Ando-Sugimoto ES, et al. Bifidobacterium strains present distinct effects on the control of alveolar bone loss in a periodontitis experimental model. *Front Pharmacol*. (2021) 12:713595. doi: 10.3389/fphar.2021.713595
- Miranda SLF, Damasceno JT, Faveri M, Figueiredo L, da Silva HD, Alencar SMA, et al. Brazilian red propolis reduces orange-complex periodontopathogens growing in multispecies biofilms. *Biofouling*. (2019) 35(3):308–19. doi: 10.1080/08927014.2019.1598976
- Pingueiro J, Piattelli A, Paiva J, Figueiredo LC, Feres M, Shibli J, et al. Additive manufacturing of titanium alloy could modify the pathogenic microbial profile: an in vitro study. *Braz Oral Res*. (2019) 33(Suppl 1):e065. doi: 10.1590/1807-3107bor-2019.vol33.0065
- Socransky SS, Haffajee AD, Cugini MA, Smith C, Kent RL. Microbial complexes in subgingival plaque. *J Clin Periodontol*. (1998) 25(2):134–44. doi: 10.1111/j.1600-051x.1998.tb02419.x
- Socransky SS, Smith C, Martin L, Paster BJ, Dewhirst FE, Levin AE. “Checkerboard” DNA-DNA hybridization. *Biotechniques*. (1994) 17(4):788–92.
- Socransky SS, Haffajee AD, Dzink JL, Hillman JD. Associations between microbial species in subgingival plaque samples. *Oral Microbiol Immunol*. (1988) 3(1):1–7. doi: 10.1111/j.1399-302X.1988.tb00596.x
- Papapanou PN, Sanz M, Buduneli N, Dietrich T, Feres M, Fine DH, et al. Periodontitis: consensus report of workgroup 2 of the 2017 world workshop on the classification of periodontal and peri-implant diseases and conditions. *J Periodontol*. (2018) 89(Suppl 1):S173–82. doi: 10.1002/JPER.17-0721
- Perez-Chaparro PJ, Goncalves C, Figueiredo LC, Faveri M, Lobao E, Tamashiro N, et al. Newly identified pathogens associated with periodontitis: a systematic review. *J Dent Res*. (2014) 93(9):846–58. doi: 10.1177/0022034514542468
- Marsh PD, Head DA, Devine DA. Ecological approaches to oral biofilms: control without killing. *Caries Res*. (2015) 49(Suppl 1):46–54. doi: 10.1159/000377732
- Miranda SLF, Damasceno JT, Faveri M, Figueiredo LC, Soares GMS, Feres M, et al. In vitro antimicrobial effect of cetylpyridinium chloride on complex multispecies subgingival biofilm. *Braz Dent J*. (2020) 31(2):103–8. doi: 10.1590/0103-6440202002630
- Ishikawa KH, Mita D, Kawamoto D, Nicoli JR, Albuquerque-Souza E, Lorenzetti Simionato MR, et al. Probiotics alter biofilm formation and the transcription of *Porphyromonas gingivalis* virulence-associated genes. *J Oral Microbiol*. (2020) 12(1):1805553. doi: 10.1080/20002297.2020.1805553
- Hajishengallis G. Periodontitis: from microbial immune subversion to systemic inflammation. *Nat Rev Immunol*. (2015) 15(1):30–44. doi: 10.1038/nri3785
- Collado MC, Vinderola G, Salminen S. Postbiotics: facts and open questions. A position paper on the need for a consensus definition. *Benef Microbes*. (2019) 10(7):711–9. doi: 10.3920/BM2019.0015
- O’Grady J, O’Connor EM, Shanahan F. Review article: dietary fibre in the era of microbiome science. *Aliment Pharmacol Ther*. (2019) 49(5):506–15. doi: 10.1111/apt.15129
- Kolenbrander PE. Oral microbial communities: biofilms, interactions, and genetic systems. *Annu Rev Microbiol*. (2000) 54:413–37. doi: 10.1146/annurev.micro.54.1.413
- Socransky SS, Haffajee AD. Dental biofilms: difficult therapeutic targets. *Periodontol* 2000. (2002) 28:12–55. doi: 10.1034/j.1600-0757.2002.280102.x
- Colombo AP, Teles RP, Torres MC, Souto R, Rosalem WJ, Mendes MC, et al. Subgingival microbiota of Brazilian subjects with untreated chronic periodontitis. *J Periodontol*. (2002) 73(4):360–9. doi: 10.1902/jop.2002.73.4.360
- Matsubara VH, Ishikawa KH, Ando-Sugimoto ES, Bueno-Silva B, Nakamae AEM, Mayer MPA. Probiotic bacteria alter pattern-recognition receptor expression and cytokine profile in a human macrophage model challenged with *Candida albicans* and lipopolysaccharide. *Front Microbiol*. (2017) 8:2280. doi: 10.3389/fmicb.2017.02280
- Vale GC, Mota BIS, Ando-Sugimoto ES, Mayer MPA. Effect of probiotics *Lactobacillus acidophilus* and *Lactocaseibacillus rhamnosus* on antibacterial response gene transcription of human peripheral monocytes. *Probiotics Antimicrob Proteins*. (2023) 15(2):264–74. doi: 10.1007/s12602-021-09832-1
- Ho SN, Acharya A, Sidharthan S, Li KY, Leung WK, McGrath C, et al. A systematic review and meta-analysis of clinical, immunological, and microbiological shift in periodontitis after nonsurgical periodontal therapy with adjunctive use of probiotics. *J Evid Based Dent Pract*. (2020) 20(1):101397. doi: 10.1016/j.jebdp.2020.101397